Brain tumour immunology and therapy group

Our Focus

Tumours of the brain and central nervous system represent approximately 2% of all cancers.

Drawing of head and brain
Martha Chekenya Enger

Main content

Although relatively rare, the most malignant, Glioblastoma Multiforme (GBM) has one of the lowest 5-year survival rates among all cancers. The patient median survival after initial diagnosis is only 14.6 months despite improved multimodal treatment. Thus there is an urgent need for more effective therapies.

Our research is focused on therapeutically targeting the Neuron-glial 2 (NG2)/CSPG4 proteoglycan which we have shown to mediate malignant progression of Glioblastoma. It is an independent predictor of negative response to temozolomide and is prognostic for poor outcome in GBM patients. We are investigating the immune status of GBM patients and delineate their mechanisms of escape from immune surveillance. Our overall aim is develop novel immunotherapy and molecular targeted therapies against NG2/CSPG4. Our overall mission is to conduct translational research that may be transferred from the bench to the bedside in the form of new, targeted therapies for brain tumour patients.